Enanta Pharmaceuticals
ENTA
197 hedge funds and large institutions have $1.42B invested in Enanta Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 77 increasing their positions, 63 reducing their positions, and 28 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 63
22% more call options, than puts
Call options by funds: $7.51M | Put options by funds: $6.18M
18% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 28
7.47% more ownership
Funds ownership: 78.29% → 85.76% (+7.5%)
2% more funds holding
Funds holding: 193 → 197 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less capital invested
Capital invested by funds: $1.75B → $1.42B (-$328M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$43M |
| 2 |
AC
Armistice Capital
New York
|
+$33.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.1M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$21.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$31.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$20.8M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$8.29M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$6.82M |
| 5 |
Two Sigma Investments
New York
|
-$6.68M |
ENTA Hedge Fund Activity: Q3 2018 in Review
197 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2018, worth a combined $1.42B — down 19% from $1.75B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ENTA positions and 28 closed out — a net gain of 5 holders — while 77 added to existing stakes and 63 trimmed.
The largest buyer was State Street, adding an estimated $43M. The largest seller was Franklin Resources, exiting entirely with an estimated $31.1M sold.
- 197 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2018, up from 193 in Q2 2018.
- Funds reported $1.42B of Enanta Pharmaceuticals stock for Q3 2018, down 19% quarter-over-quarter.
- 33 funds opened new Enanta Pharmaceuticals positions in Q3 2018 and 28 closed out, a net change of +5 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2018 was State Street, an estimated $43M added.
- The largest Enanta Pharmaceuticals seller in Q3 2018 was Franklin Resources, an estimated $31.1M sold.
Based on aggregated 13F filings for Q3 2018.